title: Cytosine arabinoside and mitoxantrone induction chemotherapy followed by bone marrow transplantation or chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
abstract: The purpose of this study was to determine the induction rate, duration of response and toxicity of cytosine arabinoside (1.0 gm/m2 i.v. over 2 h q 12 h x 8 doses days 1 through 4) and mitoxantrone (12 mg/m2 over 1 h daily x 4 doses days 3 through 6) in pediatric patients with acute myeloid leukemia (AML). Patients achieving a complete remission received either bone marrow transplantation or further chemotherapy. Twenty-seven of 37 evaluable patients (73% (95% confidence interval 59-87%)) achieved a complete remission. For all responding patients, the projected median time to relapse is 12 months. The projected 1 and 2 year disease-free survival is 47% (28-66) and 41% (21-61) with a range of follow-up of 0 to 48+ months. The major toxicity was bone marrow suppression and infection. This therapy is very active in pediatric AML and has acceptable toxicity. Some patients treated achieve prolonged survival.
authors.affiliation: Division of Hematology Oncology, Children's Hospital Medical Center, Cincinnati, OH 45229.
authors.forename: R J
authors.initials: RJ
authors.lastname: Wells
authors.forename: S H
authors.initials: SH
authors.lastname: Gold
authors.forename: C E
authors.initials: CE
authors.lastname: Krill
authors.forename: A S
authors.initials: AS
authors.lastname: Cornelius
authors.forename: R L
authors.initials: RL
authors.lastname: Byrd
authors.forename: F B
authors.initials: FB
authors.lastname: Ruymann
authors.forename: J
authors.initials: J
authors.lastname: Feusner
authors.forename: M L
authors.initials: ML
authors.lastname: White
authors.forename: M S
authors.initials: MS
authors.lastname: Cairo
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage; D012008:Recurrence; D012074:Remission Induction; D016879:Salvage Therapy
chemical_list: D003561:Cytarabine; D008942:Mitoxantrone